Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

Blood

Volumn 121, Issue 11, 2013, Pages 1968-1975

  Leleu, Xavier ^a   Attal, Michel ^b   Arnulf, Bertrand ^c   Moreau, Philippe ^d   Traulle, Catherine ^e   Marit, Gerald ^f   Mathiot, Claire ^g   Petillon, Marie Odile ^a   Macro, Margaret ^h   Roussel, Murielle ^b   Pegourie, Brigitte ⁱ   Kolb, Brigitte ^j   Stoppa, Anne Marie ^k   Hennache, Bernadette ^a   Bréchignac, Sabine ^c   Meuleman, Nathalie ^p   Thielemans, Beatrice ^a   Garderet, Laurent ^c   Royer, Bruno ^l   Hulin, Cyrille ^m   Benboubker, Lotfi ⁿ   Decaux, Olivier ^o   Escoffre Barbe, Martine ^o   Michallet, Mauricette ^e   Caillot, Denis ^q   Fermand, Jean Paul ^c   Avet Loiseau, Hervé ^c   Facon, Thierry ^a   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CHU PURPAN   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d HÔTEL DIEU   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f HAUT LÉVÊQUE HOSPITAL   (France)

^g INSTITUT CURIE   (France)

^h CHU CÔTE DE NACRE   (France)

ⁱ HÔPITAL MICHALLON   (France)

^j SERVICE DE DERMATOLOGIE   (France)

^k INSTITUT PAOLI CALMETTES   (France)

^l AMIENS UNIVERSITY HOSPITAL   (France)

^m CHU NANCY BRABOIS   (France)

ⁿ CHU BRETONNEAU   (France)

^o SERVICE DE RHUMATOLOGIE   (France)

^p JULES BORDET INSTITUTE   (Belgium)

^q Hôpital d'Enfant   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; POMALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; PYRAZINE DERIVATIVE; THALIDOMIDE;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FOLLOW UP; HUMAN; INFECTION; INFESTATION; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDIAN SURVIVAL TIME; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY MULTIPLE MYELOMA; RESPIRATORY TRACT DISEASE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; FRANCE; MEDICAL SOCIETY; MIDDLE AGED; ONCOLOGY; ORGANIZATION AND MANAGEMENT; TREATMENT FAILURE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FRANCE; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; SOCIETIES, MEDICAL; THALIDOMIDE; TREATMENT FAILURE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84877622448     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-452375     Document Type: Article

References (16)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-2520.
2. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. 2012;26(1):149-157.
3. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22(16):3269-3276.
4. Streetly MJ, Gyertson K, Daniel Y, et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141(1):41-51.
5. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008-5014.
6. Richardson PGSD, Baz R, et al. A phase 1/2 multi-center, randomized, open-label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. (abs.864). Blood. 2010;116:377. [ASH Annual Meeting Abstracts]
7. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24(11):1934-1939.
8. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118(11):2970-2975.
9. Richardson PGSD, Baz R, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. (abs.301). Blood. 2009;114:301. [ASH Annual Meeting Abstracts]
10. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.
11. Leleu X, Attal M, Moreau P, et al. Phase 2 study 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02. (abs.859). Blood. 2010;116(3):375.
12. Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(20):2475-2482.
13. Palumbo A, Larocca A, Michele Carella A, et al. A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide. Blood. 2011;118:632. [ASH Annual Meeting Abstracts]
14. Mark TM, Rodriguez M, Shah M, et al. (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. Blood. 2011;118:635. [ASH Annual Meeting Abstracts]
15. Musallam KM, Dahdaleh FS, Shamseddine AI, et al. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res. 2009;123(5):679-686.
16. Leleu X. Thrombosis in myeloma treated with IMiDs. Thromb Res. 2012;130(Suppl 1):S63-S65.